欢迎访问《中国临床药理学与治疗学》杂志官方网站，今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (2): 232-237.doi: 10.12092/j.issn.1009-2501.2025.02.010

• 药物治疗学 • 上一篇    下一篇

沙库巴曲缬沙坦在心衰患者使用中不耐受危险因素分析

王佳1，汪磊2，徐丙发3，刘峰3，温馨1，陈敏4，高寅巳5   

  1. 1安徽医科大学第三附属医院药学部，合肥  230061，安徽；2皖南医学院第一附属医院弋矶山医院医保办，芜湖  241001，安徽；3安徽医科大学第三附属医院质量与绩效管理处，合肥  230061，安徽；4安徽医科大学第三附属医院病案室，合肥  230061，安徽；5安徽医科大学第三附属医院事业发展处，合肥  230061，安徽

  • 收稿日期:2024-07-30 修回日期:2024-09-28 出版日期:2025-02-26 发布日期:2025-02-05
  • 通讯作者: 汪磊，男，研究实习员，研究方向：医院医保管理、药事管理。 E-mail： yjsyywl@qq.com
  • 作者简介:王佳，硕士，副主任药师，研究方向：临床药学。 E-mail： dmjiajia@126.com
  • 基金资助:
    安徽省医疗卫生重点专科建设项目（皖卫函[2021]273号）；2024年度校企融合发展-“齐鲁科研基金”项目重大项目（XQQL202401）

Analysis of risk factors for intolerance of valsartan with Sakubatrol in patients with heart failure

WANG Jia1, WANG Lei2, XU Binfa3, LIU Feng3, WEN Xin1, CHEN Min4, GAO Yinsi5   

  1. 1 Department of Pharmacy, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China; 2 Department of Medical Insurance, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China; 3 Department of Quality and Performance Management, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China; 4 Department of Medical Records Room, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China; 5 Department of Business Development, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China
  • Received:2024-07-30 Revised:2024-09-28 Online:2025-02-26 Published:2025-02-05

PDF (PC)

36

摘要：

目的：探讨沙库巴曲缬沙坦治疗心力衰竭（心衰）中患者不耐受的危险因素分析。方法：收集本院2023年5月至2024年5月住院124例心衰患者，采用Logistic回归分析并构建列线图分析耐受性的危险因素。结果：22例患者出现不耐受的情况，血压降低是不耐受的主要原因（P<0.05），多因素回归分析发现低的BMI［OR 95%CI 1.814（1.385-2.525）］和未合并右心衰的患者［OR 95%CI 4.998（1.552-17.301）］更容易出现药物的不耐受，模型稳定C-index 0.923（95%CI=0.863-0.975）。结论：低BMI、未合并右心衰作为影响沙库巴曲缬沙坦耐受性的危险因素，对指导临床治疗有一定的价值，但仍需要大样本的临床研究来证实。

关键词: 心力衰竭, 沙库巴曲缬沙坦, 耐受, 危险因素

Abstract:

AIM: To investigate the risk factors for intolerance to sacubitril/valsartan in the treatment of heart failure. METHODS: A total of 124 heart failure patients hospitalized in our hospital from May 2023 to May 2024 were collected. Logistic regression analysis and nomogram analysis were used to identify the risk factors for drug tolerance. RESULTS: 22 patients exhibited intolerance, with low blood pressure being the primary cause (P<0.05). Multivariate regression analysis found that patients with a low BMI (OR 95%CI 1.814(1.385-2.525)) and those without concomitant right heart failure (OR 95%CI 4.998(1.552-17.301)) were more likely to experience drug intolerance. The model had a stable C-index of 0.923 (95%CI=0.863-0.975). CONCLUSION: Low BMI and absence of right heart failure are risk factors affecting the tolerance to sacubitril/valsartan, which has certain value for guiding clinical treatment. Large-sample clinical studies are still needed to confirm these findings.

Key words: heart failure, sacubitril/valsartan, tolerance, risk factor

中图分类号: 

版权所有 © 《中国临床药理学与治疗学》编辑部
地址：安徽省芜湖市皖南医学院弋矶山医院内　邮编：241001
电话：0553-5738350　 传真：0553- 5738350　 Email：cjcpt96@163.com
本系统由北京玛格泰克科技发展有限公司设计开发